Efficacy of Atomoxetine in Children With Severe Autistic Disorders and Symptoms of ADHD

Charnsil, Chawanun

doi:10.1177/1087054710376907

Cited by 34 publications

(36 citation statements)

References 21 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This similar efficacy of atomoxetine in children with autistic disorder is in contrast with a small-scale open-label study showing no benefits of atomoxetine treatment in 12 children with a severe form of autistic disorder and ADHD symptoms (Charnsil 2011).…”

Section: Discussioncontrasting

confidence: 68%

“…2006;Charnsil 2011;Zeiner et al 2011;Fernández-Jaén et al 2013) have suggested that atomoxetine, a noradrenergic reuptake inhibitor, might be a promising treatment for ADHD symptoms in children and adolescents with ASD. We have confirmed these preliminary findings in a double-blind placebo-controlled trial followed by an open-label extension period in children and adolescents with ASD and concomitant ADHD symptoms, and have demonstrated superior efficacy of atomoxetine compared with placebo, as rated by the investigator-administered ADHD-Rating Scale (ADHD-RS), with good tolerability (Harfterkamp et al 2012).…”

mentioning

confidence: 99%

See 1 more Smart Citation

No Evidence for Predictors of Response to Atomoxetine Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms in Children and Adolescents with Autism Spectrum Disorder

Harfterkamp

Meer

Loo-Neus

et al. 2015

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 68%

mentioning

confidence: 99%

No Evidence for Predictors of Response to Atomoxetine Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms in Children and Adolescents with Autism Spectrum Disorder

Harfterkamp

Meer

Loo-Neus

et al. 2015

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

“…Positive results for atomextine are more evident among children with ASD who are cognitively higher functioning (defined as IQ >70) [45]. In a separate investigation, atomoxetine treatment yielded no observed symptom reduction in a sample of children with high ASD symptom severity [46].…”

Section: Nonstimulant Medicationsmentioning

confidence: 89%

Treatment for Co-Occurring Attention Deficit/Hyperactivity Disorder and Autism Spectrum Disorder

2012

View full text Add to dashboard Cite

Interest in the co-occurrence of attention deficit/ hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) has grown in the last decade. Research on clinical populations supports the frequent co-occurrence of ADHD traits (e.g., hyperactivity) in individuals with ASD and ASD traits (e.g., social communication deficits) in individuals with ADHD. Similar trends in co-occurring traits have been observed in population-based samples, as well as family and genetic studies of affected individuals. Despite increased interest in co-occurring ADHD and ASD, relatively little research has been devoted to treatment considerations. The vast majority of intervention research has examined pharmacological treatment using traditional ADHD medications. Relatively few psychosocial interventions have directly addressed co-occurring symptoms. Treatment development will benefit from enhanced understanding of the phenomenon of co-occurring ADHD and ASD. Key topics for future research include examining developmental trajectories of co-occurring disorders, comorbid psychiatric conditions, deficits in social skills, and the nature of executive functioning impairment in individuals with cooccurring ADHD and ASD. In the current review, research in these areas is reviewed along with recommendation for future study. Given that clinicians are routinely observing and treating individuals with co-occurring symptoms, further research will yield needed information to inform intervention development and maximize benefits for affected individuals.

show abstract

“…A great number of studies showed its effectiveness on irritability, aggressive behavior, short span of attention, increased impulsivity and hyperactivity [23,24]. Nevertheless, there was not any recent study in connection with atomoxetine treatment in MPS cases whose hyperactivity and impulsivity symptoms were prominent.…”

Section: Discussionmentioning

confidence: 99%

Atomoxetine Treatment for Attention Deficit and Hyperactivity Disorder Symptoms in a Child Who Has Mucopolysaccharidosis Type IIIB Disorder

et al. 2016

View full text Add to dashboard Cite

Mucopolysaccharidosis type III (MPS-III, Sanflippo syndrome) is one of the lysosomal storage diseases characterized by four different enzymes playing a role in catabolism of heparan sulfate substance. Type IIIB (Sanflippo B), one of them, is characterized by alpha-Nacetylglucosaminidase (NAGLU) enzyme deficiency and results in accumulation and storage of heparan sulfate in central nervous system, and then emerges itself with developmental deficiency, coarse facial features, delay in speech, mental retardation, hyperactivity, impulsivity, aggressive and disruptive behaviors, difficulty in establishing social relations, aimless hand movements, inadequate eye contact, and sleep disturbances. There are a few studies related to the treatment of neuropsychiatric symptoms of these patients. In this case, atomoxetine treatment added was shown to be effective, safe and tolerable, because risperidone treatment that the patient took was not effective in hyperactivity symptoms. A 12-year-old girl, diagnosed with MPS type IIIB (NAGLU deficiency; OMIM# 252920) when she was 5 years old, was admitted to our clinic with symptoms of hyperactivity, short span of attention, aggressive behavior, and quasi-autistic symptoms such as aimless hand movement, with risperidone use at 1.5 mg/day for approximately 1 year. After clinical and psychometric examinations, she was diagnosed with "mild mental retardation" and "attention deficit hyperactivity disorder". Atomoxetine was added at a dose of 0.5 mg/kg/day to her risperidone treatment and its dosage was gradually increased up until to 1.4 mg/kg/day. Over the followup period, her attention deficit and hyperactivity disorder (ADHD) symptoms were ameliorated, reported by both her teachers and her parents via rating scales of ADHD. Her hyperactivity and irritability levels were noticed as decreased and improved over evaluation process throughout clinical interviews. Through atomoxetine treatment process, there was not any adverse effect.

show abstract

Efficacy of Atomoxetine in Children With Severe Autistic Disorders and Symptoms of ADHD

Abstract: Atomoxetine did not benefit children with severe autistic disorder who have ADHD symptoms.

Cited by 34 publications

References 21 publications

No Evidence for Predictors of Response to Atomoxetine Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms in Children and Adolescents with Autism Spectrum Disorder

No Evidence for Predictors of Response to Atomoxetine Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms in Children and Adolescents with Autism Spectrum Disorder

Treatment for Co-Occurring Attention Deficit/Hyperactivity Disorder and Autism Spectrum Disorder

Atomoxetine Treatment for Attention Deficit and Hyperactivity Disorder Symptoms in a Child Who Has Mucopolysaccharidosis Type IIIB Disorder

Contact Info

Product

Resources

About